Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck launches Lexapro in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan.

The drug will be co-marketed in the country by Lundbeck and Japanese pharmaceutical firm Mochida, following an agreement made in January 2010.

Financial terms of the deal have not been disclosed, but Lundbeck is due to receive regulatory milestone payments and royalties on sales.

Lexapro was approved following clinical phase III studies in Japan that confirmed its efficacy and tolerability.

The companies say they estimate sales of Lexapro amounting to 3bn Yen for the first year following the launch and 33.8bn Yen during 2018 when revenue will be at its peak.

22nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics